Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel
Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel
This paper provides expert recommendations on administration of aflibercept in wet age-related macular degeneration (AMD) after Year 1 (Y1), based on a roundtable discussion held in London, UK in November 2014. The goals of treatment after Y1 are to maintain visual and anatomical gains whilst minimising treatment burden and using resources effectively. The treatment decision should be made at the seventh injection visit (assuming the label has been followed) in Y1, and three approaches are proposed: (a) eyes with active disease on imaging/examination but with stable visual acuity (VA) at the end of Y1 should continue with fixed 8-weekly dosing; (b) eyes with inactive disease on imaging/examination and stable VA should be managed using a 'treat and extend' (T&E) regimen. T&E involves treating and then extending the interval until the next treatment, by 2-week intervals, to a maximum of 12 weeks, provided the disease remains inactive. If there is new evidence of disease activity, treatment is administered and the interval to the next treatment shortened; and (c) if there has been no disease activity for ?3 consecutive visits, a trial of monitoring without treatment may be appropriate, initiated at the end of Y1 or at any time during Y2. Where possible, VA testing, OCT imaging and injection should be performed at the same visit. The second eye should be monitored to detect fellow eye involvement. In bilateral disease, the re-treatment interval should be driven by the better-seeing eye or, if the VA is similar, the eye with the more active disease.
S1-S11
McKibbin, M.
65e194c2-62e4-4a79-b442-ef92de81e625
Devonport, H.
deb0837f-1930-45a6-8b78-cff98a4503fb
Gale, R.
7e56d842-5237-4615-abef-477caee88ffc
Gavin, M.
79aa66f4-a19c-4279-80d4-949285f045bf
Lotery, A.
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
Mahmood, S.
c4d99536-7263-42a9-9816-4d353b1e329c
Patel, P.J.
e1301a3e-570d-4cdf-9419-2c7d38d48ece
Ross, A.
31d232df-e682-4729-b7d3-af01277fed01
Sivaprasad, S.
451d388e-50f3-4cfb-b963-e73461eed920
Talks, J.
f52b58b4-848f-4fed-8f01-798f3d0e1f25
Walters, G.
a693c195-5c83-4453-980d-8ed4fe302228
29 July 2015
McKibbin, M.
65e194c2-62e4-4a79-b442-ef92de81e625
Devonport, H.
deb0837f-1930-45a6-8b78-cff98a4503fb
Gale, R.
7e56d842-5237-4615-abef-477caee88ffc
Gavin, M.
79aa66f4-a19c-4279-80d4-949285f045bf
Lotery, A.
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
Mahmood, S.
c4d99536-7263-42a9-9816-4d353b1e329c
Patel, P.J.
e1301a3e-570d-4cdf-9419-2c7d38d48ece
Ross, A.
31d232df-e682-4729-b7d3-af01277fed01
Sivaprasad, S.
451d388e-50f3-4cfb-b963-e73461eed920
Talks, J.
f52b58b4-848f-4fed-8f01-798f3d0e1f25
Walters, G.
a693c195-5c83-4453-980d-8ed4fe302228
McKibbin, M., Devonport, H., Gale, R., Gavin, M., Lotery, A., Mahmood, S., Patel, P.J., Ross, A., Sivaprasad, S., Talks, J. and Walters, G.
(2015)
Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel.
Eye, 29, supplement 1, .
(doi:10.1038/eye.2015.77).
(PMID:26156564)
Abstract
This paper provides expert recommendations on administration of aflibercept in wet age-related macular degeneration (AMD) after Year 1 (Y1), based on a roundtable discussion held in London, UK in November 2014. The goals of treatment after Y1 are to maintain visual and anatomical gains whilst minimising treatment burden and using resources effectively. The treatment decision should be made at the seventh injection visit (assuming the label has been followed) in Y1, and three approaches are proposed: (a) eyes with active disease on imaging/examination but with stable visual acuity (VA) at the end of Y1 should continue with fixed 8-weekly dosing; (b) eyes with inactive disease on imaging/examination and stable VA should be managed using a 'treat and extend' (T&E) regimen. T&E involves treating and then extending the interval until the next treatment, by 2-week intervals, to a maximum of 12 weeks, provided the disease remains inactive. If there is new evidence of disease activity, treatment is administered and the interval to the next treatment shortened; and (c) if there has been no disease activity for ?3 consecutive visits, a trial of monitoring without treatment may be appropriate, initiated at the end of Y1 or at any time during Y2. Where possible, VA testing, OCT imaging and injection should be performed at the same visit. The second eye should be monitored to detect fellow eye involvement. In bilateral disease, the re-treatment interval should be driven by the better-seeing eye or, if the VA is similar, the eye with the more active disease.
Text
eye201577a.pdf
- Version of Record
Available under License Other.
More information
Published date: 29 July 2015
Organisations:
Faculty of Medicine
Identifiers
Local EPrints ID: 390412
URI: http://eprints.soton.ac.uk/id/eprint/390412
ISSN: 0950-222X
PURE UUID: 3c0052fd-6283-4d73-8bda-decddaa84054
Catalogue record
Date deposited: 01 Apr 2016 11:04
Last modified: 15 Mar 2024 03:16
Export record
Altmetrics
Contributors
Author:
M. McKibbin
Author:
H. Devonport
Author:
R. Gale
Author:
M. Gavin
Author:
S. Mahmood
Author:
P.J. Patel
Author:
A. Ross
Author:
S. Sivaprasad
Author:
J. Talks
Author:
G. Walters
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics